

Press Release

Oncobit AG Raises Over CHF 1.9 Million to Drive Growth and Expansion

Zurich, Switzerland - 27.11.2025 - Oncobit AG, a precision oncology company developing next-generation cancer monitoring solutions, today announced the successful completion of a capital increase of more than CHF 1.9 million. The financing round was supported by both existing and new investors, including private business angels and strategic partner ID Solutions (IDS).

This capital increase strengthens Oncobit's financial position and provides the resources needed to advance ongoing clinical validation, regulatory, and commercialization activities. The funds will enable Oncobit to accelerate its expansion into additional cancer indications and new markets, building on its IVDR and ISO 13485 certifications and its growing network of clinical and industry partners.

"We are very pleased to have successfully completed this financing round with the continued support of our investors and the addition of new shareholders," said Dr. Claudia Scheckel, CEO of Oncobit AG. "This investment underscores the confidence in our technology and team and allows us to continue executing on our mission to make precision cancer monitoring broadly accessible."

About:

Oncobit, a leading Swiss precision oncology company, has developed a scalable, data-driven cancer monitoring platform based on the quantitative and highly sensitive detection of cancer markers in liquid biopsies. By focusing on the most clinically impactful biomarkers and leveraging cutting-edge technology, Oncobit provides cost-effective and time-efficient solutions that enable close monitoring of a patient's cancer and support optimized therapy management. Its cloud-based data analysis and interpretation software, trained on both healthy and patient datasets, ensures robust and standardized result reporting. Oncobit's diagnostic solutions are trusted by a growing number of pharmaceutical companies, clinical laboratories, and hospital institutions.

Contact:

Dr. Claudia Scheckel
CEO
claudia.scheckel@oncobit.com
+41 78 850 07 87